Stephen Nava
Corporate Officer/Principal presso Regulator Affairs Quality Assurance Consulting Services, Inc.
Profilo
Stephen Nava is the owner of Regulator Affairs Quality Assurance Consulting Services, Inc. since 2004.
He was the Director of Regulatory Affairs & Quality Assurance at BiPar Sciences, Inc. from 2005 to 2011 and the Director of Regulatory Affairs at Acumen Sciences LLC from 2002 to 2004.
He also held the position of Vice President of Compliance & Regulatory Affairs at Sunesis Pharmaceuticals, Inc. Mr. Nava received his undergraduate degree from Texas A&M University-Kingsville.
Posizioni attive di Stephen Nava
| Società | Posizione | Inizio |
|---|---|---|
| Regulator Affairs Quality Assurance Consulting Services, Inc. | Corporate Officer/Principal | 01/01/2004 |
Precedenti posizioni note di Stephen Nava
| Società | Posizione | Fine |
|---|---|---|
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | General Counsel | 01/06/2011 |
| Acumen Sciences LLC | General Counsel | 01/01/2004 |
| VIRACTA THERAPEUTICS, INC. | Compliance Officer | - |
Formazione di Stephen Nava
| Texas A&M University-Kingsville | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
| Acumen Sciences LLC | |
| Regulator Affairs Quality Assurance Consulting Services, Inc. |
- Borsa valori
- Insiders
- Stephen Nava
